# Takeda Pharmaceutical Co Ltd: Form 20-F for the period ended Mar 31, 2022

- Company: [Takeda Pharmaceutical Co Ltd](/companies/tak.md) (CIK 1395064)
- Form: 20-F
- Filed: 2022-06-29
- Accepted by EDGAR: Jun 29, 2022, 06:05 ET
- Period: 2022-03-31
- Accession: 0001395064-22-000107
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1395064/000139506422000107/tak-20220331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1395064/000139506422000107/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2021-04-01 to 2022-03-31 | JPY 3.57tn | ifrs-full:Revenue |
| Cost of revenue | 12 months, 2021-04-01 to 2022-03-31 | JPY 1.11tn | ifrs-full:CostOfSales |
| Operating income | 12 months, 2021-04-01 to 2022-03-31 | JPY 460.84bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2021-04-01 to 2022-03-31 | JPY 72.41bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2021-04-01 to 2022-03-31 | JPY 230.06bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months, 2021-04-01 to 2022-03-31 | JPY 145.87 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2021-04-01 to 2022-03-31 | JPY 147.14 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2021-04-01 to 2022-03-31 | JPY 1.12tn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-04-01 to 2022-03-31 | JPY 123.25bn | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2022-03-31 | JPY 849.70bn | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2022-03-31 | JPY 2.59tn | ifrs-full:CurrentAssets |
| Total assets | at 2022-03-31 | JPY 13.18tn | ifrs-full:Assets |
| Current liabilities | at 2022-03-31 | JPY 2.15tn | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2022-03-31 | JPY 7.49tn | ifrs-full:Liabilities |
| Shareholders' equity | at 2022-03-31 | JPY 5.68tn | ifrs-full:EquityAttributableToOwnersOfParent |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1395064/000139506422000107/tak-20220331.htm

Filed Jun 29, 2022.
Source: SEC EDGAR, the filing index for accession 0001395064-22-000107. Last ingested by Listed: Nov 5, 2026, 16:17 ET. No prices; not investment advice.